-
Dec 4, 2024 | 
nature.com | Maximilian Merz |Danai Dima |Nausheen Ahmed |Friedrich Stölzel |Fabian Müller |Aina Oliver-Caldes | +12 more
AbstractDespite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BCMA-directed CAR T-cell therapy.
-
Dec 4, 2024 | nature.com | Maximilian Merz |Danai Dima |Nausheen Ahmed |Friedrich Stölzel |Fabian Müller |Aina Oliver-Caldes | +12 more
AbstractDespite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BCMA-directed CAR T-cell therapy.
-
Nov 29, 2024 | 
mdpi.com | Katja Seipel |Lynn Benninger |Ulrike Bacher |Thomas Pabst
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
Aug 1, 2024 | 
nature.com | Myriam Labopin |Depei Wu |Mahmoud Aljurf |Edouard Forcade |Jakob Passweg |Thomas Pabst | +7 more
AbstractCore-binding factor acute myeloid leukemia (CBF-AML) represents 12–15% of all AML cases. Although CBF positivity infers a survival advantage, overall survival (OS) remains dismal. Treatment is with cytarabine/anthracycline-based chemotherapy induction followed by high-dose cytarabine (HiDAC) consolidation. Allogeneic hematopoietic stem cell transplantation (allo-SCT) is reserved for relapse or for patients having not achieved MRD-negativity at high risk for relapse.
-
Mar 29, 2024 | 
mdpi.com | Katja Seipel |Harpreet Mandhair |Ulrike Bacher |Thomas Pabst
All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.
-
Jan 30, 2024 | 
nature.com | Meral Beksac |Xavier Poiré |Ali Bazarbachi |Thomas Pabst |Jürgen Finke |Inken Hilgendorf | +3 more
AbstractBortezomib (Vel)- Melphalan 200 mg/m2 (Mel200) (Vel-Mel) has been utilised to intensify conditioning in autologous hematopoietic stem cell transplantation (AHCT) for multiple myeloma (MM). This EBMT registry-based study compared Vel-Mel with Mel200 during upfront AHCT. Between 2010 and 2017, MM patients who received Vel-Mel (n = 292) conditioning were compared with 4,096 Mel200 patients in the same 58 centres.
-
Nov 20, 2023 | 
onlinelibrary.wiley.com | Ulrike Bacher |Evgenii Shumilov |Thomas Pabst
Currently, our understanding is limited regarding the relationship between anti-SARS-CoV-2 antibody levels post-COVID-19 vaccination and their protective value against the B.1.1.529 (Omicron) variant of SARS-CoV-2. In addition, the benefit of mRNA-based COVID-19 vaccines against the Omicron variant in patients with haematological malignancies remains to be clarified. In their paper the authors1 present the results of a prospective study from Lithuania.
-
Aug 28, 2023 | 
nature.com | Myriam Labopin |Thomas Pabst |Xi Zhang |Erlie Jiang |Alessandra Tucci |Mohamad Mohty
AbstractIn patients with acute myeloid leukemia (AML) of intermediate-risk (IR) in first remission (CR1) with no measurable residual disease (MRD negative), the choice of the best consolidation is questionable. 1122 adult patients from 196 centers, transplanted in 2010-21 were analyzed: 547 received an autologous stem cell transplantation (ASCT) and 575 a Haploidentical donor transplant.
-
Aug 23, 2023 | 
mdpi.com | Katja Seipel |Ulrike Bacher |Thomas Pabst |Scarlett Kohler
Open AccessArticleby 1,*, 1, 2 and 3 1Department for Biomedical Research, University of Bern, 3008 Bern, Switzerland2Department of Hematology, University Hospital Bern, 3010 Bern, Switzerland3Department of Medical Oncology, University Hospital Bern, 3010 Bern, Switzerland*Author to whom correspondence should be addressed. Curr. Issues Mol. Biol.
-
Jul 30, 2023 | 
onlinelibrary.wiley.com | Ulrike Bacher |Evgenii Shumilov |Thomas Pabst |Dell'Eva M
Ulrike Bacher and Evgenii Shumilov contributed equally and should both be considered as first authors. Commentary on: Pinder et al. Humoral and cellular responses to SARS-CoV-2 in patients with B-cell haematological malignancies improve with successive vaccination. Br J Haematol 2023 (Online ahead of print). doi: 10.1111/bjh.18962.
